Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News IMV Inc IMVIF

Healthcare Biotechnology

IMV Inc. is a Canada-based company. The Company has no business operations.

Add To Watchlist

Recent & Breaking News (GREY:IMVIF)

New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program

Business Wire April 3, 2019

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

Business Wire March 26, 2019

IMV Inc. to Present at Two Upcoming Investor Conferences

Business Wire March 25, 2019

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

Business Wire March 21, 2019

Une collaboration entre IMV et le Centre de Recherche du CHU de Québec-Université Laval reçoit une subvention du CQDM afin de développer une nouvelle classe thérapeutique contre le cancer de la vessie

Business Wire March 18, 2019

IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology

Business Wire March 18, 2019

IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019

Business Wire March 12, 2019

IMV annonce l’exercice partiel de l’option de souscription d’actions supplémentaires dans le cadre du placement public d’actions ordinaires par voie de prise ferme

Business Wire March 11, 2019

IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares

Business Wire March 11, 2019

IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019

Business Wire March 8, 2019

IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference

Business Wire March 7, 2019

Clôture du placement d’IMV Inc. déjà annoncé

Business Wire March 6, 2019

IMV Inc. Closes Previously Announced Public Offering

Business Wire March 6, 2019

IMV Inc. Announces Pricing of Public Offering

GlobeNewswire March 1, 2019

IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

GlobeNewswire February 28, 2019

IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA

GlobeNewswire January 29, 2019

IMV to Present at 2019 BIO CEO & Investor Conference

GlobeNewswire January 28, 2019

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

GlobeNewswire January 17, 2019

IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress

GlobeNewswire December 13, 2018

IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018

GlobeNewswire December 10, 2018